NASDAQ:OGIOrganiGram Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OrganiGram Holdings Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.52 +0.01 (+0.66 %) (As of 07/14/2020 04:00 PM ET) Add Compare Share Today's Range$1.47Now: $1.52▼$1.5550-Day Range$1.49MA: $1.76▼$2.1852-Week Range$1.09Now: $1.52▼$6.95Volume2.67 million shsAverage Volume5.04 million shsMarket Capitalization$267.07 millionP/E RatioN/ADividend YieldN/ABeta-0.02 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInstitutional OwnershipHeadlinesSocial Media OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingOrganiGram has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.11, OrganiGram has a potential upside of 302.0% from its current price of $1.52.Amount of Analyst CoverageOrganiGram has only been the subject of 4 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesOrganiGram has received 169 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOrganiGram has received 102 “underperform” votes. (Add your “underperform” vote.)Community SentimentOrganiGram has received 62.36% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about OrganiGram and other stocks. Vote “Outperform” if you believe OGI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OGI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOrganiGram does not currently pay a dividend.Dividend GrowthOrganiGram does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OrganiGram insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 11.36% of the stock of OrganiGram is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for OrganiGram are expected to grow in the coming year, from ($0.06) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OrganiGram is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OrganiGram is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganiGram has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OGI Previous Symbol CUSIPN/A CIKN/A Webwww.organigram.ca Phone1-855-961-9420Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio0.60Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$61.27 million Price / Sales4.36 Cash Flow$0.10 per share Price / Cash Flow15.06 Book Value$1.58 per share Price / Book0.96Profitability EPS (Most Recent Fiscal Year)$0.06 Net Income$-7,200,000.00 Net Margins-45.14% Return on Equity-5.33% Return on Assets-4.00%Miscellaneous Employees615 Outstanding Shares175,702,000Market Cap$267.07 million Next Earnings Date7/21/2020 (Confirmed) OptionableNot Optionable NASDAQ:OGI Rates by TradingView Receive OGI News and Ratings via Email Sign-up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter. OrganiGram (NASDAQ:OGI) Frequently Asked Questions How has OrganiGram's stock been impacted by COVID-19 (Coronavirus)? OrganiGram's stock was trading at $1.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OGI stock has decreased by 11.6% and is now trading at $1.52. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of OrganiGram? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for OrganiGram. When is OrganiGram's next earnings date? OrganiGram is scheduled to release its next quarterly earnings announcement on Tuesday, July 21st 2020. View our earnings forecast for OrganiGram. How can I listen to OrganiGram's earnings call? OrganiGram will be holding an earnings conference call on Tuesday, July 21st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were OrganiGram's earnings last quarter? OrganiGram Holdings Inc (NASDAQ:OGI) issued its quarterly earnings data on Tuesday, April, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The business earned $27.30 million during the quarter, compared to analyst estimates of $25.07 million. OrganiGram had a negative return on equity of 5.33% and a negative net margin of 45.14%. OrganiGram's revenue for the quarter was down 18.3% compared to the same quarter last year. View OrganiGram's earnings history. What price target have analysts set for OGI? 13 Wall Street analysts have issued 12-month price objectives for OrganiGram's shares. Their forecasts range from $1.72 to $12.00. On average, they anticipate OrganiGram's share price to reach $6.11 in the next twelve months. This suggests a possible upside of 302.0% from the stock's current price. View analysts' price targets for OrganiGram. Has OrganiGram been receiving favorable news coverage? Press coverage about OGI stock has been trending somewhat negative on Tuesday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. OrganiGram earned a news impact score of -1.5 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about OrganiGram. Who are some of OrganiGram's key competitors? Some companies that are related to OrganiGram include BioXcel Therapeutics (BTAI), I-Mab (ARQT), Arcus Biosciences (RCUS), Enanta Pharmaceuticals (ENTA), Phibro Animal Health (PAHC), Aimmune Therapeutics (AIMT), Arcturus Therapeutics (ARCT), Athenex (ATNX), Humanigen (HGEN), Nabriva Therapeutics (NBRV), Amphastar Pharmaceuticals (AMPH), Rhythm Pharmaceuticals (RYTM), VBI Vaccines (VBIV), Repare Therapeutics (RPTX) and Generation Bio (GBIO). View all competitors. What other stocks do shareholders of OrganiGram own? Based on aggregate information from My MarketBeat watchlists, some companies that other OrganiGram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), KushCo (KSHB), Aphria (APHA), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Innovative Industrial Properties (IIPR), NVIDIA (NVDA) and Alibaba Group (BABA). Who are OrganiGram's key executives? OrganiGram's management team includes the following people: Mr. Greg Engel, CEO & Director (Age 54)Mr. Paolo De Luca C.A., C.F.A, Chief Financial Officer (Age 46)Mr. Jeff Purcell, VP - OperationsMr. Timothy Emberg, Sr. VP of Sales & Commercial OperationsMr. Peter R. Hanson, Director of Fin. What is OrganiGram's stock symbol? OrganiGram trades on the NASDAQ under the ticker symbol "OGI." Who are OrganiGram's major shareholders? OrganiGram's stock is owned by a variety of institutional and retail investors. Top institutional investors include AdvisorShares Investments LLC (0.70%). Which institutional investors are buying OrganiGram stock? OGI stock was purchased by a variety of institutional investors in the last quarter, including AdvisorShares Investments LLC. How do I buy shares of OrganiGram? Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is OrganiGram's stock price today? One share of OGI stock can currently be purchased for approximately $1.52. How big of a company is OrganiGram? OrganiGram has a market capitalization of $267.07 million and generates $61.27 million in revenue each year. The company earns $-7,200,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. OrganiGram employs 615 workers across the globe. What is OrganiGram's official website? The official website for OrganiGram is www.organigram.ca. How can I contact OrganiGram? OrganiGram's mailing address is 35 English Dr., Moncton Z4, E1E 3X3. The company can be reached via phone at 1-855-961-9420. This page was last updated on 7/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
